Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Posts Higher Q1 Loss on Lower Revenues

Premium

MDRNA last week reported a jump in its first-quarter loss as a drop in revenues more than offset a decrease in operating costs.

MDRNA's net loss in the quarter was $9.5 million, or $0.20 per share, versus a year-ago loss of $7.3 million, or $0.23 per share.

Revenues in the quarter plummeted $14 million to $200,000, reflecting the receipt of milestones and licensing fees from partners Novartis, Roche, and Amylin Pharmaceuticals in the year-ago quarter, which were not received this year.

Research and development spending in the first quarter dropped about 13 percent, to $3.6 million from $4.1 million, reflecting patent license fees paid in the period last year that did not recur the following year.

Selling, general, and administrative costs, meanwhile, rose to $2.6 million from $2.1 million.

As of March 31, MDRNA had cash and cash equivalents totaling $3.8 million.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more